Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies. [PDF]
Eur J Clin InvestCOPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Raman S +3 more
europepmc +2 more sources
Improvements With Tiotropium Maintenance Therapy in COPD Patients Without Dyspnea. [PDF]
MedComm (2020)In a post hoc analysis of the Tie‐COPD trial, including 305 patients with mild‐to‐moderate COPD and no dyspnea (mMRC 0), 2 years of tiotropium improved lung function, lowered the annual exacerbation rate, and delayed the first clinically important deterioration, indicating benefit beyond symptom relief in a group not currently offered maintenance ...
Wang Z +15 more
europepmc +2 more sources
Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility [PDF]
, 2016 Steven Pascoe,1 Wei Wu,2 Chang-Qing Zhu,3 Dave Singh4 1GSK, Respiratory Medicines Development Center, 2PAREXEL International, Research Triangle Park, NC, USA; 3GSK, Clinical Statistics (Respiratory), Middlesex, UK; 4Medicines Evaluation Unit, University
Pascoe S, Zhu CQ, Wu W, Singh D
core +2 more sources
Bronchodilator reversibility testing in chronic obstructive pulmonary disease.
, 2003 A limited or absent bronchodilator response is used to classify chronic obstructive pulmonary disease (COPD) and can determine the treatment offered. The reliability of the recommended response criteria and their relationship to disease progression has ...
Spencer, Sally +4 more
core +5 more sources
Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease. [PDF]
, 2011 Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Developments in the understanding of COPD have led to standard guidelines for diagnosis, treatment, and spirometry assessments, which have in turn ...
James Donohue +5 more
core +1 more source
Bronchodilator reversibility in patients with asthma and persistent airflow limitation
, 2022 Bronchodilator reversibility could be explored in the ATLANTIS cohort to better understand the association between PAL and bronchodilator reversibility in the context of this new phenotype of patients with ...
Patruno, Vincenzo +3 more
core +1 more source
Therapeutic Advances in Respiratory Disease, 2015 The international guidelines on chronic obstructive pulmonary disease (COPD) recommend inhaled bronchodilators for maintenance treatment of the disease. These drugs include β2-agonists and muscarinic antagonists, which are both available as short-acting ...
Erminia Ridolo +4 more
doaj +1 more source
Evaluation of the Comparative Efficacy of Dugdhika (Euphorbia prostrata W. Aiton) Inhalation versus Salbutamol in the Management of Tamaka Shwasa (Bronchial Asthma): A Research Protocol [PDF]
Journal of Clinical and Diagnostic ResearchIntroduction: Tamaka Shwasa is an Ayurvedic respiratory disorder caused by vitiated Prana Vayu and aggravated Kapha, often worsened by dust, smoke, cold, and exertion. It resembles bronchial asthma, which affects around 300 million people globally and 15-
Bhavesh Dangore, Sadhana Misar Wajpeyi
doaj +1 more source
Impulse oscillometry bronchodilator response and asthma control [PDF]
, 2020 Impulse oscillometry is more sensitive than spirometry in detecting bronchodilator response in poorly controlled ...
Lipworth, Brian +2 more
core +1 more source
An update on the use of indacaterol in patients with COPD
Therapeutic Advances in Respiratory Disease, 2011 Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease.
Nadia S. Brienza +2 more
doaj +1 more source